{"entity":{"id":"rgenta-therapeutics","kind":"company","name":"Rgenta Therapeutics","aka":["Rgenta Therapeutics Inc"],"tldr":"Rgenta Therapeutics makes tablet medicines that act on a gene's RNA message rather than its protein; its lead drug switches off MYB, the driver of adenoid cystic carcinoma, a rare cancer of the salivary glands.","summary":"Rgenta Therapeutics, Inc., of Woburn, Massachusetts, develops oral small-molecule RNA-targeting medicines: small molecule glues that stabilise the interaction between a target RNA and the splicing machinery so that the target RNA is degraded. Its lead programme RGT-61159 inhibits production of the oncogenic transcription factor MYB and is in a phase 1a/b trial in relapsed or refractory adenoid cystic carcinoma and colorectal cancer (NCT06462183); it received FDA orphan drug designation for adenoid cystic carcinoma in September 2025, and in October 2026 the company announced an end-of-phase 2 meeting with the FDA and alignment on a phase 3 design. Preclinical work extends RGT-61159 to acute myeloid leukaemia, and the company has a CNS programme and an RSwitch gene-regulation technology. In January 2024 it joined the Leukemia & Lymphoma Society Therapy Acceleration Program, which provided strategic funding. Its first registered cancer trial, NCT06462183, was posted on ClinicalTrials.gov in June 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.rgentatx.com/"},{"label":"News and press releases","url":"https://www.rgentatx.com/news"},{"label":"ClinicalTrials.gov: phase 1a/b trial of RGT-61159 (NCT06462183)","url":"https://clinicaltrials.gov/study/NCT06462183"}],"tags":[],"related":[],"cancers":["adenoid-cystic-carcinoma","colorectal","aml"],"sections":["targeted-therapy","drug-discovery"],"technologies":["molecular-glue-platforms"],"targets":["myb"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website, news list and the January 2024 LLS release read on 29 October 2026. The domain rgenta.com is an unrelated parked domain; the company's site is rgentatx.com. Founding year not stated on the pages read. Venture rounds were not read and are not recorded."],"hq":"Woburn, MA","country":"US","companyType":"biotech","website":"https://www.rgentatx.com/","stage":"startup","investors":["lls-therapy-acceleration-program"],"funding":[{"round":"Strategic investment (LLS TAP)","year":2024,"source":"https://www.prnewswire.com/news-releases/rgenta-therapeutics-joins-the-leukemia--lymphoma-society-therapy-acceleration-program-302047063.html","note":"Amount not stated"}]},"route":"/companies/rgenta-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/"}],"target":[{"id":"myb","kind":"target","name":"MYB","route":"/targets/myb/"}],"company":[{"id":"lls-therapy-acceleration-program","kind":"company","name":"Leukemia & Lymphoma Society Therapy Acceleration Program","route":"/companies/lls-therapy-acceleration-program/"}]}}